FCR and Bevacizumab (FCR-B) Treatment in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

Patients with relapsed chronic lymphocytic leukemia (CLL) often achieve response with chemoimmunotherapy but have short remission durations. Studies have shown that patients with CLL have increased angiogenesis in the microenvironment; levels of pro-angiogenic growth factors such as VEGF and/or angi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Jain, Preetesh, Lee, Hun Ju, Qiao, Wei, Wierda, William, Benjamini, Ohad, Burger, Jan, Ferrajoli, Alessandra, Estrov, Zeev, Kantarjian, Hagop, Keating, Michael, O’Brien, Susan
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4221361/
https://ncbi.nlm.nih.gov/pubmed/25043749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28910
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items